MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - TSX:MBX - CA59501P1045 - Common Stock
0.24 CAD
-0.02 (-5.88%)
Taking everything into account, MBX scores 6 out of 10 in our fundamental rating. MBX was compared to 22 industry peers in the Biotechnology industry. While MBX has a great profitability rating, there are some minor concerns on its financial health. MBX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, MBX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year MBX has reported negative net income.
MBX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
Of the past 5 years MBX 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.85%, MBX belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
With an excellent Return On Equity value of -1.11%, MBX belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
MBX has a better Return On Invested Capital (1.38%) than 95.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROIC | 1.38% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MBX's Profit Margin has improved in the last couple of years.
The Operating Margin of MBX (3.26%) is better than 95.45% of its industry peers.
In the last couple of years the Operating Margin of MBX has grown nicely.
With an excellent Gross Margin value of 55.77%, MBX belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
In the last couple of years the Gross Margin of MBX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MBX is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
The number of shares outstanding for MBX has been increased compared to 5 years ago.
MBX has a better debt/assets ratio than last year.
2.2 Solvency
MBX has an Altman-Z score of 2.29. This is not the best score and indicates that MBX is in the grey zone with still only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.29, MBX belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that MBX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, MBX perfoms like the industry average, outperforming 59.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.29 |
ROIC/WACC0.17
WACC8.39%
2.3 Liquidity
A Current Ratio of 9.73 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.73, MBX belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
MBX has a Quick Ratio of 6.15. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a Quick ratio of 6.15. This is amongst the best in the industry. MBX outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -106.48% in the last year.
Measured over the past years, MBX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.58% on average per year.
MBX shows a decrease in Revenue. In the last year, the revenue decreased by -9.53%.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.62% yearly.
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
3.2 Future
Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 51.83% on average per year.
The Revenue is expected to grow by 21.86% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 5.94, the valuation of MBX can be described as very cheap.
Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 100.00% of the companies in the same industry.
MBX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.6 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has a very decent profitability rating, which may justify a higher PE ratio.
MBX's earnings are expected to grow with 51.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (10/20/2025, 7:00:00 PM)
0.24
-0.02 (-5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.73%
Ins Owner ChangeN/A
Market Cap33.48M
Analysts80
Price Target0.92 (283.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 | ||
| P/S | 1.58 | ||
| P/FCF | N/A | ||
| P/OCF | 55.65 | ||
| P/B | 1.14 | ||
| P/tB | 1.31 | ||
| EV/EBITDA | 11.6 |
EPS(TTM)0
EYN/A
EPS(NY)0.04
Fwd EY16.83%
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY1.8%
SpS0.15
BVpS0.21
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROCE | 1.92% | ||
| ROIC | 1.38% | ||
| ROICexc | 2.09% | ||
| ROICexgc | 2.5% | ||
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% | ||
| FCFM | N/A |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score3
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 51.1% | ||
| Cap/Sales | 4.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 25.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 | ||
| Altman-Z | 2.29 |
F-Score3
WACC8.39%
ROIC/WACC0.17
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y-68.79%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y83.08%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y17.98%
OCF growth 3Y27.25%
OCF growth 5Y155.41%